263 related articles for article (PubMed ID: 23935962)
1. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.
Cheng HH; Mitchell PS; Kroh EM; Dowell AE; Chéry L; Siddiqui J; Nelson PS; Vessella RL; Knudsen BS; Chinnaiyan AM; Pienta KJ; Morrissey C; Tewari M
PLoS One; 2013; 8(7):e69239. PubMed ID: 23935962
[TBL] [Abstract][Full Text] [Related]
2. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.
Nguyen HC; Xie W; Yang M; Hsieh CL; Drouin S; Lee GS; Kantoff PW
Prostate; 2013 Mar; 73(4):346-54. PubMed ID: 22887127
[TBL] [Abstract][Full Text] [Related]
3. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease.
Selth LA; Townley S; Gillis JL; Ochnik AM; Murti K; Macfarlane RJ; Chi KN; Marshall VR; Tilley WD; Butler LM
Int J Cancer; 2012 Aug; 131(3):652-61. PubMed ID: 22052531
[TBL] [Abstract][Full Text] [Related]
4. Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer.
Watahiki A; Macfarlane RJ; Gleave ME; Crea F; Wang Y; Helgason CD; Chi KN
Int J Mol Sci; 2013 Apr; 14(4):7757-70. PubMed ID: 23574937
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
6. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
[TBL] [Abstract][Full Text] [Related]
7. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer.
Tinay I; Tan M; Gui B; Werner L; Kibel AS; Jia L
Prostate; 2018 Sep; 78(12):927-937. PubMed ID: 29748958
[TBL] [Abstract][Full Text] [Related]
8. Discovery of extracellular vesicles derived miR-181a-5p in patient's serum as an indicator for bone-metastatic prostate cancer.
Wang Y; Fang YX; Dong B; Du X; Wang J; Wang X; Gao WQ; Xue W
Theranostics; 2021; 11(2):878-892. PubMed ID: 33391510
[No Abstract] [Full Text] [Related]
9. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
Jones DZ; Schmidt ML; Suman S; Hobbing KR; Barve SS; Gobejishvili L; Brock G; Klinge CM; Rai SN; Park J; Clark GJ; Agarwal R; Kidd LR
BMC Cancer; 2018 Apr; 18(1):421. PubMed ID: 29653561
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers.
van Schooneveld E; Wouters MC; Van der Auwera I; Peeters DJ; Wildiers H; Van Dam PA; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Feb; 14(1):R34. PubMed ID: 22353773
[TBL] [Abstract][Full Text] [Related]
13. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
14. The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.
Ishteiwy RA; Ward TM; Dykxhoorn DM; Burnstein KL
PLoS One; 2012; 7(12):e52106. PubMed ID: 23300597
[TBL] [Abstract][Full Text] [Related]
15. A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer.
Daniel R; Wu Q; Williams V; Clark G; Guruli G; Zehner Z
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28621736
[TBL] [Abstract][Full Text] [Related]
16. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers.
Brunet Vega A; Pericay C; Moya I; Ferrer A; Dotor E; Pisa A; Casalots À; Serra-Aracil X; Oliva JC; Ruiz A; Saigí E
Oncol Rep; 2013 Jul; 30(1):320-6. PubMed ID: 23673725
[TBL] [Abstract][Full Text] [Related]
17. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.
Farran B; Dyson G; Craig D; Dombkowski A; Beebe-Dimmer JL; Powell IJ; Podgorski I; Heilbrun L; Bolton S; Bock CH
Carcinogenesis; 2018 Apr; 39(4):556-561. PubMed ID: 29471417
[TBL] [Abstract][Full Text] [Related]
18. microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer.
Bhagirath D; Yang TL; Bucay N; Sekhon K; Majid S; Shahryari V; Dahiya R; Tanaka Y; Saini S
Cancer Res; 2018 Apr; 78(7):1833-1844. PubMed ID: 29437039
[TBL] [Abstract][Full Text] [Related]
19. Biomarker microRNAs for prostate cancer metastasis: screened with a network vulnerability analysis model.
Lin Y; Chen F; Shen L; Tang X; Du C; Sun Z; Ding H; Chen J; Shen B
J Transl Med; 2018 May; 16(1):134. PubMed ID: 29784056
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
